1. Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies
2. U.S. Food & Drug Administration. FDA approves Opdualag for unresectable or metastatic melanoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdualag-unresectable-or-metastatic-melanoma (2022, accessed 14 October 2022)
3. U.S. Food & Drug Administration. FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma (2022, accessed 28 October 2022)
4. U.S. Food & Drug Administration, FDA approves toripalimab-tpzi for nasopharyngeal carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-toripalimab-tpzi-nasopharyngeal-carcinoma (2023, accessed 5 March 2024)
5. U.S. Food & Drug Administration, FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel (2023, accessed 5 March 2024)